Folger Nolan Fleming Douglas Capital Management Inc. boosted its position in shares of Medtronic PLC (NYSE:MDT) by 45.7% during the first quarter, according to its most recent filing with the SEC. The fund owned 6,121 shares of the medical technology company’s stock after buying an additional 1,920 shares during the period. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Medtronic PLC were worth $493,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Baystate Wealth Management LLC boosted its position in Medtronic PLC by 40.9% in the first quarter. Baystate Wealth Management LLC now owns 1,959 shares of the medical technology company’s stock worth $157,000 after buying an additional 569 shares in the last quarter. North Star Investment Management Corp. boosted its position in Medtronic PLC by 4.4% in the first quarter. North Star Investment Management Corp. now owns 1,973 shares of the medical technology company’s stock worth $159,000 after buying an additional 83 shares in the last quarter. LeJeune Puetz Investment Counsel LLC purchased a new position in Medtronic PLC during the fourth quarter worth approximately $167,000. Liberty Capital Management Inc. boosted its position in Medtronic PLC by 45.6% in the first quarter. Liberty Capital Management Inc. now owns 2,111 shares of the medical technology company’s stock worth $170,000 after buying an additional 661 shares in the last quarter. Finally, Hudock Capital Group LLC boosted its position in Medtronic PLC by 0.6% in the first quarter. Hudock Capital Group LLC now owns 2,184 shares of the medical technology company’s stock worth $175,000 after buying an additional 12 shares in the last quarter. 83.17% of the stock is currently owned by institutional investors and hedge funds.
Shares of Medtronic PLC (MDT) opened at 85.17 on Monday. The company has a market cap of $115.75 billion, a P/E ratio of 29.47 and a beta of 1.03. The firm has a 50-day moving average of $87.57 and a 200-day moving average of $81.81. Medtronic PLC has a 52-week low of $69.35 and a 52-week high of $89.72.
Medtronic PLC (NYSE:MDT) last issued its quarterly earnings results on Thursday, May 25th. The medical technology company reported $1.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.02. Medtronic PLC had a net margin of 13.56% and a return on equity of 12.72%. The business had revenue of $7.92 billion for the quarter, compared to analyst estimates of $7.86 billion. During the same quarter in the prior year, the business posted $1.27 EPS. Medtronic PLC’s revenue for the quarter was up 4.6% compared to the same quarter last year. Equities research analysts forecast that Medtronic PLC will post $4.95 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 26th. Shareholders of record on Friday, July 7th will be paid a dividend of $0.46 per share. This is a positive change from Medtronic PLC’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Wednesday, July 5th. This represents a $1.84 dividend on an annualized basis and a yield of 2.16%. Medtronic PLC’s dividend payout ratio is presently 63.67%.
ILLEGAL ACTIVITY WARNING: “Medtronic PLC (NYSE:MDT) Shares Bought by Folger Nolan Fleming Douglas Capital Management Inc.” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/07/24/medtronic-plc-nysemdt-shares-bought-by-folger-nolan-fleming-douglas-capital-management-inc.html.
MDT has been the topic of a number of research analyst reports. CIBC reissued a “buy” rating on shares of Medtronic PLC in a research note on Friday, May 26th. Needham & Company LLC reissued a “buy” rating and issued a $95.00 target price (up previously from $91.00) on shares of Medtronic PLC in a research note on Thursday, May 25th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $93.00 target price (up previously from $87.00) on shares of Medtronic PLC in a research note on Thursday, May 25th. Royal Bank Of Canada reissued a “buy” rating and issued a $85.00 target price on shares of Medtronic PLC in a research note on Tuesday, April 18th. Finally, UBS AG reissued a “buy” rating and issued a $95.00 target price (up previously from $94.00) on shares of Medtronic PLC in a research note on Tuesday, May 30th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $89.16.
In other Medtronic PLC news, EVP Bryan C. Hanson sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $88.57, for a total transaction of $1,062,840.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Richard H. Anderson purchased 5,600 shares of the business’s stock in a transaction on Wednesday, June 21st. The shares were bought at an average price of $88.90 per share, for a total transaction of $497,840.00. Following the purchase, the director now directly owns 71,910 shares in the company, valued at approximately $6,392,799. The disclosure for this purchase can be found here. Corporate insiders own 0.25% of the company’s stock.
Medtronic PLC Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.
